About SpePharm Holding
A European specialty pharmaceutical company dedicated to hospital and specialist drugs.SpePharm is a European specialty pharmaceutical company focused on acquiring, registering and marketing high medical value specialty medicines, essentially for the hospital market.
Missing: SpePharm Holding's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: SpePharm Holding's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Latest SpePharm Holding News
Oct 27, 2017
Zoomactu Vous êtes ici : Publié le 27 octobre 2017 par M.L Dans le cadre d’un litige qui l’opposait au néerlandais SpePharm (Spepharm Holding Bv – siège à Amsterdam, Pays-Bas – Fabrication de préparations pharmaceutiques) et sa filiale SpeBio, Onxeo (siège à Paris /75 – développement de médicaments innovants pour le traitement des maladies orphelines dans le domaine de l’oncologie – effectif estimé : 60) a été condamnée par le tribunal de commerce de Paris. Au total, la société française devra verser presque 9 millions d’euros. Ce montant est toutefois à relativiser : Onxeo détenant 50% de SpeBio, la somme effectivement déboursée par la biotech devrait s’élever aux alentours de 4,5 millions d’euros. Onxeo envisage de faire appel de la décision du tribunal. En savoir plus ?
SpePharm Holding Frequently Asked Questions (FAQ)
When was SpePharm Holding founded?
SpePharm Holding was founded in 2006.
What is SpePharm Holding's latest funding round?
SpePharm Holding's latest funding round is Other Investors.
Who are the investors of SpePharm Holding?
Investors of SpePharm Holding include Signet Healthcare Partners, Sanders Morris Harris Private Equity, Indevus Pharmaceuticals, BioAlliance Pharma and TVM Capital Life Science.
Who are SpePharm Holding's competitors?
Competitors of SpePharm Holding include Zogenix, EUSA Pharma, Ikaria, Cadence Pharmaceuticals, Santarus and 11 more.
Compare SpePharm Holding to Competitors
IVREA Pharmaceuticals is a specialty pharmaceutical company focused on clinical development and commercialization of novel prescription pharmaceuticals for the treatment of dermatologic conditions. IVREA's pharmaceuticals leverage topical delivery technologies.
Roxro Pharma is an early-stage specialty pharmaceutical company dedicated to identifying, licensing, and developing compounds in specialized disease areas with significant sales potential, such as pain management. Roxro will pursue product development with the objective of commercializing these products. Niche products will not be developed by major pharmaceutical companies because they will not fuel their growth requirements. Foreign and biotechnology companies with compounds that have a limited sales potential will not be partnered with major pharmaceutical companies. Therefore there are a number of products not being developed even though they are efficacious, safe and satisfy an unmet medical need.
Aerogen specializes in the design, manufacture and commercialization of aerosol drug delivery systems. Aerogen's patented vibrating mesh technology turns liquid medication into a fine particle mist, gently and effectively delivering drugs to the lungs of patients, enhancing outcomes and giving healthcare professionals a higher level of confidence and control.
Pradama, Inc. is a pharmaceutical company focused on the development and commercialization of products to treat bone diseases and disorders. Pradama is developing compounds that target bone with the initial two products designed for osteoporosis treatment and an antineoplastic compound for the treatment of bone metastases.
Tarsa Therapeutics develops therapies for the treatment and prevention of osteoporosis and related bone diseases. The company is developing OSTORA, an oral formulation of calcitonin for the treatment and prevention of postmenopausal osteoporosis. OSTORA is expected to be the first approved oral calcitonin, a natural hormone with a long history of safety and efficacy as an osteoporosis therapy. Availability of an oral calcitonin for osteoporosis is expected to generate wider use as doctors and patients are seeking new options that are safe and effective.
Nautilus Neurosciences is a neurology-focused specialty pharmaceutical company committed to providing the healthcare community with relevant products and services that directly benefit those affected by neurological disorders. In the first half of 2010, Nautilus intends to launch a novel product, CAMBIA¯¿½ (diclofenac potassium for oral solution).
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.